Navigation Links
Heteroduplex Analysis Using the DCode System

Paul Zoller and Theresa Redila-Flores
Bio-Rad Laboratories, Hercules, California


Introduction
Heteroduplex Analysis (HA) is a commonly used mutation screening method due to its simplicity. The technique is based on conformational differences in double-stranded DNA caused by the formation of heteroduplex molecules.1 Heteroduplex molecules have a mismatch in the double-strand, causing a distortion in its usual conformation. This distortion or altered conformation can be detected on polyacrylamide gels due to slower migration than the corresponding homoduplex molecules. Heteroduplexes are generated during PCR* of a heterozygous individual or by adding mutant and wild-type DNA in the same PCR reaction or by denaturing and renaturing a mixture of mutant and wild-type DNA. Both mutant and wild-type samples are run on the same gel to analyze differences in mobility. Heteroduplex molecules with as little as one mismatch can show a different mobility in a gel from homoduplex molecules. Polyacrylamide analogs have been developed, such as DEMTM (Detection Enhancing Matrix) from Bio-Rad, which enhance the ability to detect mutations in heteroduplex samples when compared to conventional polyacrylamide gels.2

In this experiment, we show that Heteroduplex Analysis on the DCode universal mutation detection system can be used to analyze mutations in the cystic fibrosis gene.


Method
The test samples consist of wild-type and mutant DNA samples from the cystic fibrosis gene exons 7 and 10. The heterozygous mutations from exon 7 were 1154insTC, two base insertion (+TC) and ΔF311, three base deletion (-TTC). The mutations from exon 10 were a heterozygous ΔF508, three base deletion (-CTT), a heterozygous compound sample Q493 (C to T) and ΔF508 (-CTT), a homozygous ΔF508 (-CTT) and a heterozygous ΔI507, three base deletion (-ATC). Samples were provided by Dr. L. Silverman, University of North Carolina School of Medicine (Chapel Hill, NC). Genomic DNA from both wild-type and mutant samples were amplified by PCR to create end products of 289 bp for exon 7 and 369 bp for exon 10.

A 16 cm x 20 cm, 0.75 mm thick, 1x DEM gel made up in 0.6x TBE buffer (54 mM Tris, 54 mM boric acid, 1.2 mM EDTA) was used. 1.5 liters of 0.6x TBE buffer was added to the lower electrophoresis tank and 350 ml of 0.6x TBE buffer was added to the upper chamber in the DCode system. 5 l (200300 ng) of each amplified sample was mixed with 5 l 2x gel loading dye (70% glycerol, 0.05% bromophenol blue, 0.05% xylene cyanol, 2 mM EDTA) and electrophoresed on the DCode system at 100 V for 16 hours at room temperature. After electrophoresis, the gel was stained in 50 g/ml ethidium bromide in 0.6x TBE buffer for 5 minutes and destained in buffer for 10 minutes. The gel was imaged under UV transillumination.


Results and Discussion
Figure 1 shows the mutant and wild-type samples from the cystic fibrosis gene run on the DCode system. The mutant samples from exon 7 (Figure 1.A) in lanes 2 and 3 resolve into two heteroduplex bands (upper bands) and a homoduplex band (lower band). The two heteroduplex bands in the mutant samples from exon 10 (Figure 1.B) in lanes 2, 3 and 5 are resolved from the homoduplex bands. The ΔF508 homozygous mutant in lane 4 has no heteroduplex bands, and the homoduplex bands migrate the same as the wild-type. Under these conditions, it was not possible to resolve the two homoduplex bands of the ΔF508 mutant. This mutation may be detected if heteroduplexes are formed by mixing the mutant and wild-type samples together, then denaturing and renaturing the DNA.

The ability to resolve the heteroduplex bands in the mutant samples makes it possible to distinguish between the mutant and wild-type samples. Heteroduplex Analysis can be used as a method for screening heterozygous mutations in the cystic fibrosis gene using the DCode system.


References
1. Nagamine, C.M., Chan, K. and Lau, Y-F.C., Hum. Genet., 45, 337-339 (1989).

2. White, M., Carvalho, M., Derse, D., OBrien, S. and Dean, M., Genomics, 12, 301-306 (1992).


*The Polymerase Chain Reaction (PCR) process is covered by patents owned by Hoffmann-LaRoche. Use of the PCR process requires a license.


back to top
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Epitope-Tagging Vectors for Functional Analysis in Yeast
3. Map and Link Human Genetic Disorders with SSLP Analysis
4. CastAway Precast Gels for Rapid Automated DNA Sequence Analysis
5. Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf cMaster RTplusPCR System
6. Structural Analysis of Glycosylated Peptides in Complex Mixtures with Ion Trap MSn
7. Use of Transcriptor Reverse Transcriptase in Microarray Analysis
8. Increased Sensitivity in Microarray Analysis
9. Gene-Expression Analysis of TP, DPD, and TS Using the LightCycler mRNA Quantification KitsPLUS
10. Agilent 2100 Bioanalyzer Automated Analysis System
11. Analysis of Microarray Data
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heteroduplex Analysis Using the DCode System

(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... Study Results for Memory and Cognition Validate Clinical ... ... Amarin Corporation plc,(NASDAQ: AMRN ) ("Amarin" or "Company") announced ... using ultra-pure,eicosapentanoic acid (EPA) have been published in the "Journal ...
... Sample Analysis Systems-, PHILADELPHIA, Sept. 24 ... whole genome imaging and analytic,platforms for clinical ... the issuance of a patent for a ... The patent covers a novel technique for,the ...
... Shire management team, CAMBRIDGE, Mass., and ... SHP, Nasdaq: SHPGY, TSX: SHQ),the global specialty ... been appointed President of its Human Genetic ... than 20 years of,management, regulatory affairs, manufacturing ...
Cached Biology Technology:Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 2BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 2Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 3Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business 4
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... new species of monkey flower, created by the union ... of a stream in Scotland. Genetic changes in this attractive yellow-flowered ... rare example of a brand new species that has originated in ... and some crops are thought to have originated in this way, ...
... Pharmaceuticals today announced that research collaborators at the Peter ... established, for the first time, that RNA Polymerase I ... and that its inhibition selectively activates p53 to kill ... the findings show that Cylene,s Pol I inhibitor, CX-5461, ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Rare glimpse into the origin of species 2Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: